Molecular genetics of meningiomas: A systematic review of the current literature and potential basis for future treatment paradigms

Neurosurgical Focus

Volumn 30, Issue 5, 2011, Pages

  Pham, Martin H ^a   Zada, Gabriel ^a   Mosich, Gina M ^a   Chen, Thomas C ^a   Giannotta, Steven L ^a   Wang, Kai ^a,b   Mack, William J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

DNA sequencing; Genetics; Genomics; Meningioma; Skull base

Indexed keywords

GENETIC ASSOCIATION; GENETICS; HUMAN; MENINGIOMA; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SKULL BASE TUMOR; TUMOR SUPPRESSOR GENE;

GENES, TUMOR SUPPRESSOR; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; ONCOGENES; SIGNAL TRANSDUCTION; SKULL BASE NEOPLASMS;

EID: 79955779647     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2011.2.FOCUS1117     Document Type: Review

References (102)

1. Abramovich CM, Prayson RA: Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome. Am J Clin Pathol 114:84-92, 2000.
2. Aichholzer M, Bertalanffy A, Dietrich W, Roessler K, Pfs-terer W, Ungersboeck K, et al: Gamma knife radiosurgery of skull base meningiomas. Acta Neurochir (Wien) 142:647-653, 2000.
3. Al-Mefty O, Fox JL, Smith RR: Petrosal approach for petroclival meningiomas. Neurosurgery 22:510-517, 1988.
4. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ: Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 20:623-631, 2010.
5. Bek EL, McMillen MA: Endothelins are angiogenic. J Cardiovasc Pharmacol 36 (5 Suppl 1):S135-S139, 2000.
6. Bondy M, Ligon BL: Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 29:197-205, 1996.
7. Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al: Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669, 2001.
8. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008.
9. Carstens C, Messe E, Zang KD, Blin N: Human KRAS oncogene expression in meningioma. Cancer Lett 43:37-41, 1988.
10. Chauvet AE, Kesava PP, Goh CS, Badie B: Selective intraarterial gene delivery into a canine meningioma. J Neurosurg 88: 870-873, 1998.
11. Cirulli ET, Goldstein DB: Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11:415-425, 2010.
12. Couldwell WT, Fukushima T, Giannotta SL, Weiss MH: Petroclival meningiomas: surgical experience in 109 cases. J Neurosurg 84:20-28, 1996.
13. Cuevas IC, Slocum AL, Jun P, Costello JF, Bollen AW, Riggins GJ, et al: Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65:5070-5075, 2005.
14. Davidson L, Fishback D, Russin JJ, Weiss MH, Yu C, Pagnini PG, et al: Postoperative Gamma Knife surgery for benign meningiomas of the cranial base. Neurosurg Focus 23(4):E6, 2007.
15. Davidson L, Zada G, Yu C, Petrovich Z, Pagnini PG, Zee CS, et al: Delayed toxicity from gamma knife radiosurgery to lesions in and adjacent to the brainstem. J Clin Neurosci 16:1139-1147, 2009.
16. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, et al: Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum 17. Genet 97:632-637, 1996.
17. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bono P et al: Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin. Hum Genet 97:638-641, 1996.
18. Detta A, Kenny BG, Smith C, Logan A, Hitchcock E: Correlation of protooncogene expression and proliferation and meningiomas. Neurosurgery 33:1065-1074, 1993.
19. Diedrich U, Eckermann O, Schmidtke J: Rare Ha-ras and c-mos alleles in patients with intracranial tumors. Neurology 38:587-589, 1988.
20. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005, 2010.
21. Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, Durbin RM, et al: A map of human genome variation from population-scale sequencing. Nature 467:1061-1073, 2010.
22. Easton DF, Eeles RA: Genome-wide association studies in cancer. Hum Mol Genet 17 (R2):R109-R115, 2008.
23. Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, et al: Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 94:111-117, 2001.
24. Fernandez HA, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R, et al: Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res 82:156-162, 1999.
25. Ferner RE: Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6:340-351, 2007.
26. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003.
27. Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, et al: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol 35:1395-1407, 2009.
28. Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 3:89-96, 1992.
29. Friend KE, Khandwala HM, Flyvbjerg A, Hill H, Li J, Mc-Cutcheon IE: Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines. Growth Horm IGF Res 11:84-91, 2001.
30. Gautreau A, Louvard D, Arpin M: ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 14: 104-109, 2002.
31. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, et al: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 16:4155-4164, 2010.
32. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kit-tiniyom K, et al: Loss of DAL-1, a protein 41-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 9:1495-1500, 2000.
33. Halaka AN, Bunning RA, Bird CC, Gibson M, Reynolds JJ: Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J Neurosurg 59:461-466, 1983.
34. Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, et al: Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery 63:771-781, 2008.
35. International HapMap Consortium: The International Hap-Map Project. Nature 426:789-796, 2003.
36. Iwai Y, Yamanaka K, Ishiguro T: Gamma knife radiosurgery for the treatment of cavernous sinus meningiomas. Neurosurgery 52:517-524, 2003.
37. Jagannathan J, Oskouian RJ, Yeoh HK, Saulle D, Dumont AS: Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base 18:173-187, 2008.
38. Johnson MD, Okediji E, Woodard A: Transforming growth factor-beta effects on meningioma cell proliferation and signal transduction pathways. J Neurooncol 66:9-16, 2004.
39. Kaartinen V, Gonzalez-Gomez I, Voncken JW, Haataja L, Faure E, Nagy A, et al: Abnormal function of astroglia lacking Abr and Bcr RacGAPs. Development 128:4217-4227, 2001.
40. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, et al: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:271-275, 1997.
41. Kazumoto K, Tamura M, Hoshino H, Yuasa Y Enhanced expression of the sis and c-myconcogenes in human meningiomas. J Neurosurg 72:786-791, 1990.
42. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820-823, 1971.
43. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, et al: NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 194:367-372, 2001.
44. Laurendeau I, Ferrer M, Garrido D, DHaene N, Ciavarelli P Basso A, et al: Gene expression prof ' ling of the hedgehog signaling pathway in human meningiomas. Mol Med 16:262-270, 2010.
45. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, et al: The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465:473-477, 2010.
46. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ: Meningiomas, in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System: World Health Organization Classification of Tumours. Lyon: IARC Press, 2000, pp 176-184.
47. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, et al: Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121-7126, 2005.
48. Manolio TA, Brooks LD, Collins FS: A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118:1590-1605, 2008.
49. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009.
50. Mardis ER, Wilson RK: Cancer genome sequencing: a review. Hum Mol Genet 18 (R2):R163-R168, 2009.
51. Mathiesen T, Lindquist C, Kihlström L, Karlsson B: Recurrence of cranial base meningiomas. Neurosurgery 39:2-9, 1996.
52. Mawrin C, Perry A: Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379-391, 2010.
53. Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 46:16-21, 1990.
54. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9:356-369, 2008.
55. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, et al: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94:487-492, 2001.
56. Messerini L, Vitelli F, De Vitis LR, Mori S, Calzolari A, Palmirotta R, et al: Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables. J Pathol 182:380-384, 1997.
57. Metzker ML: Sequencing technologies-the next generation. Nat Rev Genet 11:31-46, 2010.
58. Mizoue T, Kawamoto H, Arita K, Tominaga A, Kurisu K: Secretion of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by meningiomas detected by cell immunoblot analysis. Acta Neurochir (Wien) 141:481-486, 1999.
59. Morita A, Coffey RJ, Foote RL, Schiff D, Gorman D: Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. J Neurosurg 90:42-49, 1999.
60. Morozova O, Marra MA: Applications of next-generation sequencing technologies in functional genomics. Genomics 92: 255-264, 2008.
61. Nakasu S, Hirano A, Shimura T, Llena JF: Incidental meningiomas in autopsy study. Surg Neurol 27:319-322, 1987.
62. Nozaki M, Tada M, Kashiwazaki H, Ham ou MF, Diserens AC, Shinohe Y, et al: p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol 11:296-305, 2001.
63. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachami-mov AO, Ramesh V, et al: Inactivation patterns of NF2 and DAL-1/4 1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162:135-139, 2005.
64. Ohba S, Kobayashi M, Horiguchi T, Onozuka S, Yoshida K, Ohira T, et al: Long-term surgical outcome and biological prognostic factors in patients with skull base meningiomas. Clinical article. J Neurosurg [epub ahead of print December 17, 2010. DOI: 10.3171/2010.11. JNS10701].
65. Paek SH, Kim DG, Park CK, Phi JH, Kim YY, Im SY, et al: The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas. Oncol Rep 16:49-56, 2006.
66. Pallen MJ, Loman NJ, Penn CW: High-throughput sequencing and clinical microbiology: progress, opportunities and challenges. Curr Opin Microbiol 13:625-631, 2010.
67. Pećina-Slaus N, Nikuseva Martić T, Deak AJ, Zeljko M, Hrasćan R, Tomas D, et al: Genetic and protein changes of E-cadherin in meningiomas. J Cancer Res Clin Oncol 136: 695-702, 2010.
68. Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, et al: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol 12:1278-1290, 2010.
69. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (eds): Meningiomas, in Louis DN, Ohgaki H, Wiestler OD, et al: World Health Organization Classification of Tumours of the Central Nervous System, ed 4. Lyon: IARC Press, 2007, pp 164-172.
70. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC: "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85:2046-2056, 1999.
71. Petrovich Z, Yu C, Giannotta SL, Zee CS, Apuzzo ML: Gamma knife radiosurgery for pituitary adenoma: early results. Neurosurgery 53:51-61, 2003.
72. Peyrard M, Fransson I, Xie YG, Han FY, Ruttledge MH, Swahn S, et al: Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Hum Mol Genet 3:1393-1399, 1994.
73. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-196, 2010.
74. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463:184-190, 2010.
75. Pool JE, Hellmann I, Jensen JD, Nielsen R: Population genetic inference from genomic sequence variation. Genome Res 20: 291-300, 2010.
76. Ragel BT, Jensen RL: Molecular genetics of meningiomas. Neurosurg Focus 19(5):E9, 2005.
77. Raymond FL, Whittaker J, Jenkins L, Lench N, Chitty LS: Molecular prenatal diagnosis: the impact of modern technologies. Prenat Diagn 30:674-681, 2010.
78. Ress A, Moelling K: Bcr is a negative regulator of the Wnt signalling pathway. EMBO Rep 6:1095-1100, 2005.
79. Riemenschneider MJ, Perry A, Reifenberger G: Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045-1054, 2006.
80. Salhia B, Rutka JT, Lingwood C, Nutikka A, Van Furth WR: The treatment of malignant meningioma with verotoxin. Neoplasia 4:304-311, 2002.
81. Schloss PD, Handelsman J: Metagenomics for studying uncul-turable microorganisms: cutting the Gordian knot. Genome Biol 6:229, 2005.
82. Schwechheimer K, Zhou L, Birchmeier W: E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas. Virchows Arch 432:163-167, 1998.
83. Seizinger BR, Rouleau G, Lane AH, Ozelius LJ, Faryniarz AG, Iannazzi J, et al: DNA linkage analysis in Von Recklinghausen neurofibromatosis. J Med Genet 24:529-530, 1987.
84. Simon M, Boström JP, Hartmann C: Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 60:787-798, 2007.
85. Skiriute D, Tamasauskas S, Asmoniene V, Saferis V, Skaumi-nas K, Deltuva V, et al: Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas. J Neurooncol 102:89-94, 2010.
86. Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A: The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 10:1204-1212, 2008.
87. Subach BR, Lunsford LD, Kondziolka D, Maitz AH, Flick-inger JC: Management of petroclival meningiomas by stereotactic radiosurgery. Neurosurgery 42:437-445, 1998.
88. Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K, et al: Establishment of a human malignant meningioma cell line with amplified c-myconcogene. Cancer 64:2243-2249, 1989.
89. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177, 2000.
90. Van Havenbergh T, Carvalho G, Tatagiba M, Plets C, Samii M: Natural history of petroclival meningiomas. Neurosurgery 52:55-64, 2003.
91. Varghese JS, Easton DF: Genome-wide association studies in common cancers-what have we learnt? Curr Opin Genet Dev 20:201-209, 2010.
92. Varjosalo M, Taipale J: Hedgehog: functions and mechanisms. Genes Dev 22:2454-2472, 2008.
93. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, et al: Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146: 827-832, 1995.
94. Werner T: Next generation sequencing in functional genomics. Brief Bioinform 11:499-511, 2010.
95. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, et al: Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423:448-452, 2003.
96. Wozniak K, Piaskowski S, Gresner SM, Golanska E, Bieniek E, Bigoszewska K, et al: BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet Cytogenet 183:14-20, 2008.
97. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, et al: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114:249-256, 2005.
98. Xie J, Johnson RL, Zhang X, Bare JW, Waldman FM, Cogen PH, et al: Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 57: 2369-2372, 1997.
99. Yee G, Rycroft R, Phillips C, English C, Carson S, Schwenn M, et al: 2009-2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in Eighteen States in 2002-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2009.
100. Zada G, Pagnini PG, Yu C, Erickson KT, Hirschbein J, Zelman V, et al: Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas. Neurosurgery 67:322-329, 2010.
101. Zhang MX, Zhao X, Wang ZG, Zhao WM, Wang YS: Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation. J Cancer Res Clin Oncol 136:981-988, 2010.
102. Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C: The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One 5:e11231, 2010.